Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K8 | P41279 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | PYGL | P06737 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | SELE | P16581 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | PYGM | P11217 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL47045 | 0.90 | AKR1C3 (0.47) | KDM4EGLAPYGLPOLBAKR1C3 | |
| SCHEMBL489914 | 0.85 | SLC6A4 (0.47) | KDM4EGLAPOLBAKR1C3CYP3A4 | |
| SCHEMBL12726139 | 0.84 | SORT1 (0.46) | KDM4EGLAPOLBAKR1C3AKR1C2 | |
| SCHEMBL21327649 | 0.84 | KDM4E (0.54) | KDM4EPOLBAKR1C3AKR1C2MCL1 | |
| SCHEMBL490103 | 0.84 | MAPT (0.50) | KDM4EGLAPOLBAKR1C3AKR1C2 | |
| SCHEMBL2371063 | 0.83 | KDM4E (0.48) | MAP3K8KDM4EGLAPYGLPOLB | |
| SCHEMBL19474926 | 0.83 | NCEH1 (0.46) | KDM4EGLAPYGLPOLBAKR1C3 | |
| SCHEMBL26936314 | 0.81 | KDM4E (0.56) | KDM4EGLAPYGLPOLBAKR1C3 | |
| SCHEMBL20281786 | 0.79 | KDM4E (0.51) | KDM4EGLAPYGLPOLBAKR1C3 | |
| SCHEMBL12682946 | 0.79 | MAP3K8 (0.40) | MAP3K8KDM4EPOLBCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150554-B2 | Fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150554-B2 | Fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-8999967-B2 | Tricyclic fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999967-B2 | Tricyclic fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2012050918-A2 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICAL, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | HAVCR2, HCCS, LIPC | MAP3K8 2852/4885KDM4E 4230/4885GLA 3744/4885 |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | HAVCR2, HCCS, ZC3HAV1 | MAP3K8 2887/4885KDM4E 3819/4885GLA 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.